AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00936247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin + electrolyte solution
Description: Albumin 5% as colloid component and NaCl 0.9% as electrolyte component
Study NCT00894829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heparin sodium - Eurofarma
Description: Heparin sodium 5.000 UI - Eurofarma
Study NCT00894829 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: heparin sodium - APP
Description: Heparin sodium APP 5.000 USP
Study NCT02018380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shock Absorbing Insole (SofSole Athletes Plus)
Description: The shock absorbing insole used in this study was the SofSole Athletes Plus, (Implus Inc, Durham, NC), recommended by the manufacturer for repetitive activities such as running and walking. It is readily available in most athletic shoe stores, retailing for under $20.00. The insole is full-length with a curved last made of Implus XP that has a shore A durometer reading of 60 (0 = softest to 100 = hardest).
Study NCT02020564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speed of Processing Training
Study NCT02020564 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Study NCT00005838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: shark cartilage extract AE-941
Description: Given orally
Study NCT00005838 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT00005838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00005838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: Given IV
Study NCT00005838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV
Study NCT00005838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vinorelbine tartrate
Description: Given IV
Study NCT00005838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00005838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Given IV
Study NCT00005838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00005838 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: Given IV
Study NCT01218594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostatin
Description: 7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
Study NCT03288688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program and education
Description: The exercise program comprises warm-ups, exercises and cool-downs and aims to improve recruitment, strength and endurance of postural muscle groups that are key to the work of a musician. Basic activation exercises progress to dynamic and resisted exercises as well as functional musical movements. There is a series of six exercises of increasing difficulty for each of the following bodily regions: hips, back, neck, shoulders and abdominals.~Topics to be discussed in the educational presentation and e-mails include healthy practice habits, activity dosage, the importance of physical activity, how the body adapts to workload and physical stressors, and instructions pertaining to the exercise program.
Study NCT00005838 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT00005838 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT01617447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Flexibly dose administered orally once daily
Study NCT01437527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anamorphic Micro software
Description: Body image therapy with Anamorphic Micro software
Study NCT01437527 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: therapy as usual
Description: Body image therapy as usual
Study NCT03233022 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
Study NCT03233022 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
Study NCT03233022 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
Study NCT03597919 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sabin IPV
Description: We select one Sabin IPV product, produced by Kunming Bio institute, which is available for China's National Immunization Program in the selected study sites.
Study NCT03597919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin IPV
Description: We select one Sabin IPV product, produced by Kunming Bio institute, which is available for China's National Immunization Program in the selected study sites.
Study NCT02351141 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hyperpolarized Noble Gas MRI
Description: Hyperpolarized Helium-3 and/or Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
Study NCT02713919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted German PRO-SELF© Plus Pain Control Program
Description: Two in-home visits (60 minutes) with at least weekly follow-up (visit or telephone call according to algorithm): Structured and tailored components; review of pain diary with participant, provision of information on pain medication, nurse coaching regarding pain self-management, detailed side-effect management plan, if distressing side-effects arise, re-evaluation together with participant at each subsequent visit.
Study NCT02944773 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facilitated tucking device
Description: 20 newborns are using a facilitated tucking device weight during the procedure to assess the level of stress
Study NCT03180645 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test product (Moisturising cream)
Description: Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
Study NCT03180645 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Positive control (Commercial market place moisturising cream)
Description: Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
Study NCT03180645 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: No treatment
Study NCT01562860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pronator Teres Release
Description: Surgical release of median nerve compression
Study NCT01562860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dual compression release
Description: Both the carpal tunnel compression and the pronator teres compression will be released on the same day.
Study NCT01562860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dual compression release
Description: both procedures will be done on the same day
Study NCT01562860 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: median nerve release only
Description: only the carpal tunnel compression is released
Study NCT04252092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory training
Description: 15 session,20 minutes sensory training program
Study NCT04252092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: 15 session,20 minutes electrical stimulation program
Study NCT01970774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MTM with PGx
Description: Patients will attend MTM sessions and receive PGx testing
Study NCT03372291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual leukemia care with all the supportive care measures instituted by the leukemia team
Study NCT03372291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: Psychological intervention is focused on educating patients about leukemia and how to cope with its treatment
Study NCT02956304 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PMv stimulation (iTBS)
Description: PMv stimulation (iTBS)
Study NCT02956304 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PMv inhibition (cTBS)
Description: PMv inhibition (cTBS)
Study NCT04368988 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2
Description: Intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M adjuvant (0.5 mL).
Study NCT01496547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensive chemo - RIC preparation
Description: The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
Study NCT03089710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mini-fluid challenge
Description: Mini-fluid challenge test with 100mL colloid infusion in 1 min
Study NCT01231204 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline) Continuous Infusion
Description: Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with normal saline. The normal saline infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
Study NCT01231204 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ropivicaine 0.4% Continuous Infusion
Description: Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with 0.4%Ropivicaine. The 0.4%Ropivicaine infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
Study NCT02956304 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control (SHAM)
Description: Control (SHAM)
Study NCT03624309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Plus Docetaxel
Description: Anlotinib (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
Study NCT03624309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (75mg/m2 IV d1)
Study NCT04881851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inositol + alpha lipoic acid
Description: Inositol 1000 mg + alpha lipoic acid 400 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
Study NCT04881851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inositol
Description: Inositol 1000 mg + folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
Study NCT04881851 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid (placebo comparator)
Description: Folic acid 200 ug: 1 sachet at breakfast and 1 sachet at dinner
Study NCT01667146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHARLAP mechanical ventilation strategy
Description: Pressure control ventilation to maintain tidal volume 4-6 ml/kg and plateau pressure ≤ 30 cmH2O while tolerating respiratory acidosis if pH > 7.15; daily staircase recruitment manoeuvre and individualised PEEP titration.
Study NCT01667146 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group mechanical ventilation strategy
Description: Mechanical ventilation based on the ARDSnet protocol using volume control ventilation with tidal volume 6 ml/kg, plateau pressure ≤ 30 cmH2O and FiO2/PEEP titration according to a FiO2/PEEP/oxygen saturation combination chart. This has been modified for Australian and New Zealand practice to allow pressure control and pressure support ventilation.
Study NCT02813395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: Low Level Laser Therapy was applied at four points to the dominant upper limb of the volunteers on the muscle belly of the biceps. Delineation was done using a measuring tape from the elbow joint line to the acromion marked at points corresponding to 20%, 30%, 40% and 50% of this distance, focusing the application on the muscle belly region, thereby excluding the tendinous region.~An 808 nm equipment was used for applying laser therapy, with a power of 100 mW and total energy of 20 J.
Study NCT02813395 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: Laser application simulation with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
Study NCT01007422 — intervention group
Intervention type: BEHAVIORAL
Intervention: telephone-based intervention
Study NCT01007422 — intervention group
Intervention type: OTHER
Intervention: communication intervention
Study NCT01007422 — intervention group
Intervention type: OTHER
Intervention: intervention by caregiver
Study NCT01007422 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Study NCT01007422 — intervention group
Intervention type: OTHER
Intervention: survey administration
Study NCT01007422 — intervention group
Intervention type: PROCEDURE
Intervention: end-of-life treatment/management
Study NCT01007422 — intervention group
Intervention type: PROCEDURE
Intervention: pain therapy
Study NCT01007422 — intervention group
Intervention type: PROCEDURE
Intervention: psychosocial assessment and care
Study NCT00823277 — intervention group
Intervention type: OTHER
Intervention: Chronic care multidisciplinary intervention of childhood obesity
Description: Overweight and obese Children, 5-20 Years old, followed by Paediatricians and other Health Personals (multidisciplinary team). Included at their first visit in the clinic (baseline)and follow-up after \~ 1 Year.
Study NCT03056391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: >50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~\<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine.
Study NCT02011347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT02421913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S(+)-Ketamine
Description: S(+)-Ketamine 0,3mg/kg/hr intraoperative
Study NCT02111291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase SANTYL® Ointment
Description: Daily application directly to the ulcer bed, approximately 2 mm thick.
Study NCT02111291 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Hydrogel (if needed) and foam dressing
Description: Daily application of hydrogel directly to the ulcer bed (if necessary), covered with foam dressing
Study NCT03597607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Smoking Cessation Group
Description: This group will meet with the pharmacist more frequently and for longer periods than other groups.
Study NCT03597607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abbreviated Smoking Cessation Group
Description: This group will meet with the pharmacist less frequently and for shorter periods in comparison to the intensive group.
Study NCT03759041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Pre-Treatment
Description: Four times per day dosing of vancomycin pre-treatment
Study NCT03759041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Vancomycin Pre-Treatment
Description: Four times per day dosing of placebo pre-treatment
Study NCT03759041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-287
Description: Once-daily dosing of SER-287
Study NCT03759041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SER-287
Description: Once-daily dosing of Placebo for SER-287
Study NCT02406352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Digital Colposcope with probe
Description: Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study.~The standard of care for research participants will not change.
Study NCT03831945 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VRC-HIVMAB060-00-AB (VRC01)
Description: VRC01 is a broadly neutralizing human mAb targeted against the HIV-1CD4 binding site. As single intravenous infusion of VRC01(40 mg/kg) plus10-1074 (30mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
Study NCT03831945 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10-1074
Description: 10-1074 is a recombinant, fully human mAb of the IgG1 lambda isotype that specifically binds to the base of the V3 loop within HIV-1 envelope gp-120. A single intravenous infusion of VRC01 (40 mg/kg) plus 10-1074 (30 mg/kg) or placebo will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
Study NCT03831945 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Description: 2 sequential infusions of normal saline placebo in matching volumes to antibody infusions will be administered after the first analytical treatment interruption phase once the subject's plasma viremia is > or = 200 copies/mL.
Study NCT04581057 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Specific blood sampling
Description: A 30 ml blood sample (6 EDTA tubes) will be taken at inclusion in the study, in addition to the blood sample taken as part of the routine care.~This sampling is carried out for :~* Search for CHIP-associated mutations in circulating leukocytes~* Plasma determination of IL-1β, IL-6, IL-10 and TNF-α
Study NCT00673075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
Study NCT00673075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
Study NCT01524094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)
Description: Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.
Study NCT01524094 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)
Description: Cytoreductive surgery has the goal of completely resecting all visible tumor tissue in the abdomen. Sequential postoperative intraperitoneal chemotherapy has the purpose of an adjuvant treatment to eradicate microscopic residual tumor and prevent recurrences in the abdomen. The chemotherapy regimen consisted of intraperitoneal 5-fluorouracil 550 mg/ m2 and intravenous isovorin 30 mg/ m2 day 1-6 med cycles every 4-6 weeks. Six cycles were planned.
Study NCT00408031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated GLY site.
Study NCT02071342 — intervention group
Intervention type: PROCEDURE
Intervention: angioplasty
Description: patients with acute coronary syndrome and coronary angioplasty with bioresorbable vascular scaffold.
Study NCT01021553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK557296
Description: 50 mg GSK557296
Study NCT01021553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK557296
Description: 150 mg GSK557296
Study NCT01021553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo